Prescription Required(Save Upto 85%)
Lynparza Olaparib 150 mg Tablets is used in the treatment of ovarian and HER2-negative metastatic breast cancer.
It is an anticancer medication that works by inhibiting the growth of select tumor cell lines in vitro and decrease tumor growth in both as monotherapy or following chemotherapy.
Lynparza 150mg Tablet is an anticancer drug belonging to the category of poly adenosine diphosphate-ribose polymerase (PARP) inhibitor.
Tell your healthcare provider before starting treatment, if you have been diagnosed with problems in your lungs, liver, heart, or kidneys.
Lynparza 150mg Tablet works by inhibiting PARP enzymes, blocks the repair of single-stranded DNA, and ultimately hinders the growth and development of cancer cells.
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them.
Ans :Bracanat 150mg Tablet and other PARP inhibitors effectively prevent ovarian cancer relapse by 40-70%.
Ans : Lynparza 150mg Tablet is a targeted anticancer drug belonging to the category of PARP inhibitors. It specifically acts against ovarian cancer due to mutation in BRCA genes.
Ans :PARP inhibitors are intended to be taken for as long as your healthcare provider recommends. Some studies suggest taking PARP inhibitors for up to 2 years..
Ans :Lynparza 150mg Tablet is usually indicated as maintenance therapy after a person completes a platinum-based chemotherapy regimen for ovarian cancer. However, newer studies are evaluating its solitary efficacy in treating different types of cancers.
Ans :Lynparza 150mg Tablet may increase the risk of bone marrow diseases (myelodysplastic syndrome or Acute Myeloid Leukemia), lung problems (pneumonitis), and blood clots (venous thromboembolism).
